The second-quarter numbers make the divergence difficult to miss. Eli Lilly reported revenue of $23.0 billion, up 48% year over year. Mounjaro generated $9.9 billion and Zepbound another $4.9 billion. Lilly subsequently raised its full-year revenue forecast to between $85 billion and $87 billion.
Novo Nordisk, meanwhile, reported adjusted Q2 sales growth of 7% at constant exchange rates, with adjusted operating profit rising 11%. The Danish company also raised its adjusted full-year outlook. Both companies are growing. They are not currently growing at remotely the same pace.
Tirzepatide has become an enormous business
Mounjaro revenue increased 91% year over year in the quarter. Zepbound sales rose 46%. Combined, the two tirzepatide brands generated almost $15 billion in three months.
That scale changes how investors need to think about Lilly. The company is no longer simply a pharmaceutical group with a promising obesity franchise. Its incretin portfolio is rapidly becoming one of the largest commercial franchises in global medicine.
And Lilly is still expanding capacity. The company announced another $4.5 billion commitment to its Indiana manufacturing sites alongside the results, an indication that supply remains a strategic issue rather than a solved one.
Novo's problem is not a lack of demand
It would be easy to read the divergence as evidence that the obesity market itself is weakening. The numbers do not support that conclusion.
Novo said adjusted sales increased 7% at constant exchange rates, driven by GLP-1 volume growth across markets. Its reported operating profit was complicated by comparison effects and DKK6.3 billion of non-cash impairment charges associated with pipeline assets.
The issue for investors is therefore competitive positioning rather than the disappearance of demand. The obesity market remains enormous. What is changing is the distribution of growth within it.
The pipeline now matters almost as much as current sales
Lilly also said its Phase 3 clinical data package for retatrutide is complete for obesity, obstructive sleep apnea and knee osteoarthritis pain, with US regulatory submission planned for the first quarter of 2027.
That adds another dimension to the rivalry. Investors are not simply comparing Mounjaro and Zepbound against Novo's existing portfolio. They are pricing competing pipelines, manufacturing capacity, reimbursement, international expansion and the prospect of increasingly convenient drugs. The next scheduled checkpoints are on the earnings calendar.
For Lilly, the challenge is maintaining a growth rate that has already created enormous expectations. For Novo, the challenge is more immediate: demonstrate that it can reaccelerate while defending its position in a category it helped create. The GLP-1 market is still expanding. The competitive gap inside it is becoming the more interesting chart.